Euromed has acquired Probelte Biotechnologies (ProbelteBio) a leading manufacturer of nutraceutical ingredients located in Murcia, Spain. ProbelteBio was founded in 1970 and specializes in environmentally friendly extraction technology on ingredients known to be beneficial as part of the “Mediterranean diet.” Their location in the agriculturally rich region known as the “Garden of Europe” in Murcia provides ready access to plant origin raw materials and traceability for their products like olive and pomegranate.

ProbelteBio prides itself on producing botanical extracts with proven efficacy and has generated an impressive portfolio of scientific studies. Both the extraction technology and published efficacy studies have been protected as intellectual property in the form of 10 patents and numerous product trademarks that have been received by the firm.

The firm invested 23 million dollars in 2011 in advanced nutraceutical processing and as a result has obtained six industrial certifications. These include FSSC 22000, UNE-EN ISO 22000 and ISO TS 22002-1 and manufacturing oversight under HACCP compliance in its 215,000-square foot facility.

“The future for our fast-paced technologically rapidly advancing society is for consumers to obtain nutritionally enhanced foods and disease retarding dietary supplements,” according to Guy Woodman, General Manager of Euromed USA, Inc. “ProbelteBio helps us satisfy this societal need by bringing a similar philosophy of sustainability and traceability as Euromed to the control of their locally sourced agricultural raw materials and concentrated extracts.”

The addition of ProbelteBio accelerates Euromed’s product portfolio expansion and innovation objectives, particularly into vegetable and fruit based nutraceutical ingredients. The corporate research and development department will continue to be based at its Barcelona headquarters where its expanded laboratories and innovation center will be completed in December 2017.

ABOUT EUROMED
Euromed supplies standardized botanical and herbal extracts and natural active substances for use in the pharmaceutical, health food, and cosmetics industries. By extracting the necessary chemicals, the company can guarantee its products meet the precise chemical specifications. Euromed was founded 46 years ago, and in 2016 the company was acquired by The Riverside Company; the US facility is in Bridgeville, Pennsylvania. For more information, visit www.euromedusa.com  or email Be****@********sa.com or call 412-279-8808.

admin

euromedgroup.elonial.com

ABALife fig fruit extract for glycemic control and carbohydrate metabolism.

Euromed SA has received an exclusive license agreement with BioTherapeutics Inc. for patented technology for abscisic acid (ABA).

The patents licensed by Euromed are titled: “Method of using abscisic acid to treat diseases and disorders” (Patent numbers 7,741,1367 and 8,367,727, and the Inventors are Josep Bassaganya-Riera, Raquel Hontecillas, and Amir Guri). The invention relates to biologically active compounds (ABA) that treat and prevent insulin resistance and impaired glucose tolerance. The patents provide protection for structure-function claims related to ABA and maintenance of healthy blood sugar levels and similar statements.

By partnering with BioTherapeutics, “Euromed continues to seek ingredient innovation that will address broad-based health concerns for consumers globally,” commented Javier Roig CEO of Euromed S.A. “ABA Life, our tradename for this ingredient can provide a safe and effective dietary supplement to aid in correcting impaired carbohydrate metabolism.”

ABA Life is a proprietary all-natural line of botanical extracts that contain abscisic acid. The first product to be introduced is an extract from fig fruit, Ficus carica L. Figs, a long-standing foodstuff of Mediterranean populations grow naturally throughout Spain and have one of the highest concentrations of abscisic acid found in nature. About 92% of Americans do not consume adequate fruits and vegetables and may be deficient in ABA. ABA Life delivers the scientifically proven health benefits of ABA while avoiding additional calories associated with eating figs.

“We are looking forward to partner with Euromed to accelerate the development of new ABA-containing nutritional products for glycemic control,” said Josep Bassaganya-Riera, president and CEO of BioTherapeutics. “We anticipate that the first product containing ABAlife will be a functional health water to be launched in the U.S. market under the Pervida brand. The Pervida brand is currently commercializing Pervida Immune for gut and immune health, and in 2018 it will launch Pervida Control, the first ABA-containing beverage for glycemic control.”

The average American consumes 19.5 teaspoons of sugar every day. That quantity adds up to 66 pounds of added sugar consumed per person every year. Sugar increases the level of glucose in the blood and causes the pancreas to release insulin. Higher insulin leads to more storage of dietary calories as fat. ABA Life assists insulin release and lowers blood glucose.

According to Centers For Disease Control, another 86 million adults – more than one in three U.S. adults – have prediabetes, where their blood sugar levels are higher than normal but not high enough to be classified as type 2 diabetes.

Without weight loss and moderate physical activity, 15 to 30% of people with prediabetes will develop type 2 diabetes within five years.

According to the latest U.S. dietary survey, about 92% of the population might have a deficient intake of ABA due to their deficient intake of fruits and vegetables that is under the recommended 4.5 servings per day. ABA consumed as a dietary supplement will be an aid in improving glucose tolerance in healthy individuals and those seeking health enhancement.

admin

euromedgroup.elonial.com

Our teams from Europe and US were busy at Stand NN123 providing information on the broad list of Euromed extracts, including our newest ABAlife, an innovative fig fruit extract standardized in abscisic acid (ABA), indicated for blood glucose management, officially launched at SSW.

The development of ABAlife is the result of a partnership with BioTherapeutics (BTI) that was announced at SSW. As a part of this deal, BTI has granted an exclusive license to Euromed for patented technology for abscisic acid (ABA).

Dr. Josep Bassaganya-Riera, President and CEO of BTI, gave a presentation at our stand describing the key features of this innovative extract.

admin

euromedgroup.elonial.com

The Riverside Company has acquired Euromed S.A. (Euromed). Euromed provides standardized herbal extracts and natural active substances for the pharmaceutical, dietary supplement and cosmetic industries.

Euromed is a corporate carve-out from Meda, a Swedish pharmaceutical company. Based in Barcelona, Euromed processes more than 4,000 tons of raw materials every year to produce approximately 600 tons of high-quality extract to meet the needs of more than 350 customers in 35 countries worldwide.

“Euromed is one of the world’s leading suppliers of pharmaceutical and dietary supplements and meets the high standards to merit full certification by the U.S. Food and Drug Administration and Korean FDA, EU GMP guidelines, and other globally recognized high quality certifications,” said Riverside Partner Karsten Langer. “It’s a worldwide leader in its top four product categories, and has unique capability to provide custom solutions for clients. We’re excited about its next growth chapter.”

Riverside has extensive experience in its Healthcare Specialization, having completed 85 deals in the space, including supplement and pharmaceutical companies. Riverside plans to drive growth by boosting production, improving operations and continuing to invest in research and development. Euromed serves a variety of international customers and will benefit from Riverside’s global reach and resources to expand overseas, especially in the U.S. and Asia, where the dietary supplements market is expected to grow significantly in the coming years.

“Euromed presents an exciting opportunity in a field with high entry barriers and significant growth avenues, where Riverside has enjoyed success,” said Riverside Principal Rafael Álvarez-Novoa. “We look forward to partnering with the company to enhance its capabilities and results.”

Working on the transaction with Langer and Álvarez-Novoa for Riverside were Vice President Damien Gaudin, Associate Hidde Van Kerckhoven and Research Analyst Philippe Niessen. Álvarez-Novoa also sourced the deal for Riverside.

Financing for the transaction was provided by European Capital. Fidentiis, Uria and Deloitte advised Riverside on the investment.

About The Riverside Company

The Riverside Company is a global private equity firm focused on acquiring growing businesses valued at up to $300 million. Since its founding in 1988, Riverside has invested in more than 400 transactions. The firm’s international portfolio includes more than 80 companies.

admin

euromedgroup.elonial.com

Other certifications at EUROMED: GMP from Spanish authorities, HACCP, ISO9001, HALAL, Kosher, BIO certification.

admin

euromedgroup.elonial.com